ADVISORY/Experts Available to Discuss Passing of Project BioShield.Business Editors ADVISORY... --(BUSINESS WIRE) TOPIC: On a 99-0 vote the Senate today approved Project BioShield, according to an article by the Associated Press. Over the 10-year life of the project, $5.6 billion of government dollars will cover the expense of research, drugs and incentives for companies to contribute to a medical arsenal of antiterrorism an·ti·ter·ror·ist adj. Intended to prevent or counteract terrorism; counterterror: antiterrorist measures. an drugs & vaccines that otherwise may not have market viability. The project also will fund medical centers to treat victims, and finance rescue efforts. Under BioShield some treatments will be allowed to bypass the approval process, allowing the government to distribute them prior to FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approval during an emergency. EXPERTS: ExpertSource can offer several highly qualified experts to comment on this story: Bob Marsella, Vice President of Business Development of Hollis-Eden Pharmaceuticals Inc., can speak about how this bill will spur development of "next-generation" medical countermeasures to bioterrorism. After Sept. 11, Hollis-Eden focused its research energy on Neumune(TM), an immune-boosting steroid hormone steroid hormone n. See steroid. that the company is developing for protection against radiation sickness radiation sickness, harmful effect produced on body tissues by exposure to radioactive substances. The biological action of radiation is not fully understood, but it is believed that a disturbance in cellular activity results from the chemical changes caused by after a nuclear or radiological attack. Marsella can discuss how passage of Project BioShield will create a market for drugs that may save lives if the US is besieged be·siege tr.v. be·sieged, be·sieg·ing, be·sieg·es 1. To surround with hostile forces. 2. To crowd around; hem in. 3. with weapons of mass destruction Weapons that are capable of a high order of destruction and/or of being used in such a manner as to destroy large numbers of people. Weapons of mass destruction can be high explosives or nuclear, biological, chemical, and radiological weapons, but exclude the means of transporting or , and how the opportunity to receive contracts for payment on delivery will accelerate investment in innovative biotech and pharmaceutical companies. 858-587-9333; bmarsella@holliseden.com. Dwight R. Stickney, M.D., Vice President of Medical Affairs, Hollis-Eden, is a practicing radiation oncologist radiation oncologist Radiation therapist A radiologist specialized in using radioactive substances and x-rays to treat tumors and CA; an oncologist who uses various formats of radiation to manage CA Salary ± $200K. See Oncologist. who can address the effects of nuclear or radiological exposure. Stickney joined Hollis-Eden from the Radiation Oncology Division of Radiological Associates of Sacramento Medical Group Inc., in Sacramento, Calif. where he served as an oncologist since 1993. Stickney also has served as the Director of Radiation Research for Scripps Clinic and Research Foundation in La Jolla, Calif. In addition, he taught in medical academia as Associate Professor of Radiation Medicine at Loma Linda University Founded in 1905, Loma Linda University (LLU) is a private, Christian, coeducational, health sciences university located in Southern California 60 miles east of Los Angeles close to San Bernardino and near beaches, mountains, and the desert. School of Medicine and has served as Director of the International Order of Foresters Cancer Research Laboratory and on the Board of Directors of the American Cancer Society American Cancer Society, n.pr established in 1913, this national volunteer-based health organization is committed to the elimination of cancer through prevention and treatment and to diminishing cancer suffering through advocacy, scholarship, research, , California Division. Stickney is certified as a Diplomat of the American Board of Internal Medicine The American Board of Internal Medicine (ABIM) is a non-profit, independent physician organization in the U.S. that certifies physicians who practice in internal medicine and its sub-specialties. and Hematology and a Diplomat of the American Board of Radiology, Therapeutic Radiology. 858-587-9333; dstickney@holliseden.com. Dr. Kenneth I. Kaitin, Tufts Center for the Study of Drug Development, can discuss national and worldwide trends in pharmaceutical innovation, regulation, and public policy. Dr. Kaitin has written extensively on factors that contribute to the slow pace and high cost of pharmaceutical R&D, and the impact of regulatory and legislative initiatives to speed drug development and approval. He is a former President of the Drug Information Association, and he serves on the faculty of the European Center for Pharmaceutical Medicine. Contact Info: 781-326-9980; lowy@bus-com.com ExpertSource cannot guarantee the immediate availability of these experts or their familiarity with this specific issue. ExpertSource provides academic and industry experts to the media at no charge. Journalists are encouraged to submit queries to ExpertSource when seeking experts on specific subjects. An online registration form is available at http://www.businesswire.com/. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion